Chemotherapy News and Research

Latest Chemotherapy News and Research

New weapon in the fight against cancer

A cancer diagnosis is not necessarily a death sentence. There are now quite a number of possibilities to treat cancer. In addition to radiotherapy and chemotherapy, so-called radionuclide treatment has also become an important component in the fight against the mutated cells. It involves injecting radioactive elements, so-called nuclides, into the patient's circulatory system.

17 Jun 2011

New Australian drug shows positive response in patients with multiple myeloma blood cancer

Australian monoclonal antibody company, Immune System Therapeutics Limited (IST), today announced it would double patient recruitment in its Phase II trial for a breakthrough antibody treatment for terminal blood cancer.

16 Jun 2011

Adaptimmune melanoma trial opening

Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington University, St. Louis, Missouri.

16 Jun 2011

Initial data from COMPLETE study on peripheral T-cell lymphoma presented at ICML 2011

Allos Therapeutics, Inc. today announced the presentation of initial data from COMPLETE, an international registry designed to address the urgent need for an increased understanding of the treatment patterns and outcomes for patients with peripheral T-cell lymphoma.

16 Jun 2011

Boehringer Ingelheim, Zealand Pharma partner to develop Type-2 diabetes and obesity agonists

Today, Zealand Pharma, a Copenhagen based biopharmaceutical company, and Boehringer Ingelheim, one of the world's leading pharmaceutical companies, jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.

16 Jun 2011

Seattle Genetics brentuximab vedotin, dacetuzumab clinical data to be presented at ICML 2011

Seattle Genetics, Inc. today announced that data from its brentuximab vedotin and dacetuzumab programs will be presented at the 11th International Conference on Malignant Lymphoma being held June 15-18, 2011 in Lugano, Switzerland.

16 Jun 2011

Potential new drug therapies targeting genetic mutations benefit lung-cancer patients

Some lung-cancer patients at UT Southwestern Medical Center are responding well to potential new drug therapies targeting genetic mutations. Their participation in a national study is helping to forge new avenues to attack the disease.

16 Jun 2011

Sheep diagnoses breast cancer

A British woman from Wiltshire discovered she had cancer after her sheep butted her in the breast. Emma Turner (41) was giving Alfie some medicine when he suddenly became aggressive and began head-butting her violently in the chest.

16 Jun 2011

Galectin strengthens cancer drug patent portfolio in Europe

Galectin Therapeutics Inc. today announced that the European Patent Office has granted the Company a new patent, No. 02731178.6, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer".

15 Jun 2011

OncoSec Medical third quarter net loss increases to $491,000

OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, today reported financial results for the quarter ended April 30, 2011.

15 Jun 2011

Biomoda receives U.S. patent to expand the use of CyPath assay for treatment of cancer

Cancer diagnostics company Biomoda, Inc. received Notice of Allowance for a U.S. Patent issued today that expands on use of the CyPath assay to include patient response to cancer therapy during the treatment phase of the disease.

15 Jun 2011

JEM published paper identifies new gene mutations in patients with chronic lymphocytic leukemia

A paper published online on June 13 in the Journal of Experimental Medicine identifies new gene mutations in patients with chronic lymphocytic leukemia (CLL)—a disease often associated with lack of response to chemotherapy and poor overall survival.

14 Jun 2011

Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

Ambit Biosciences Corporation and Astellas Pharma Inc. announced today results from a planned interim analysis in an ongoing Phase 2 study evaluating AC220, a potent and selective FLT3 inhibitor.

14 Jun 2011

Policy issues related to dual-eligible patients, cancer medication coverage attract headlines

The Associated Press reports that seniors are facing Medicare cost barriers which sometimes lead them to not fill cancer drug prescriptions. Also, CQ HealthBeat reports that a special team within the Department of Health and Human Services is working on finding ways to save money and improve care for patients on both Medicare and Medicaid.

13 Jun 2011

Sarcoma UK releases inspiring film about people's experiences of living with bone cancer

Sarcoma UK releases an inspiring film about the experiences of people living with a rare form of cancer of soft tissue and bone, as part of Sarcoma Awareness Week.

13 Jun 2011

Second course of treatment could cure head and neck cancer

A new study has determined predictors that can better identify patients who will benefit from a potentially toxic second course of treatment, which offers a small but real chance of cure in select patients with head and neck cancer.

13 Jun 2011

Cancer survivors and friends to attend San Diego's Survivor Beach event on June 19

Hundreds of surfers, cancer survivors and friends will gather together, with surfboards in hand, on La Jolla Shores Sunday, June 19 for an annual San Diego tradition: Survivor Beach. Attendees will place surfboards along the edge of the shore, nose-to-tail, from Scripps Pier down La Jolla Shores, with the goal of forming a record-breaking line of several hundred surfboards.

13 Jun 2011

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc., announced today that data on ADCETRIS (brentuximab vedotin) in relapsed or refractory Hodgkin lymphoma patients were featured in an oral presentation at the 16th Congress of the European Hematology Association (EHA) in London.

13 Jun 2011

Hyperthermia prevents repair of tumor cells

BSD Medical Corporation, a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that a study published in the Proceedings of the National Academy of Sciences demonstrated that hyperthermia can be a powerful tool to inhibit the ability of cancer cells to repair the DNA damage caused by radiation or chemotherapy.

10 Jun 2011

Ambit Biosciences raises $30 million through Series D-2 equity financing

Ambit Biosciences (Ambit), an emerging biopharmaceutical company engaged in the development of kinase inhibitors for the treatment of cancer and other conditions, today announced that it has completed a Series D-2 round of equity financing, raising $30 million in new capital.

10 Jun 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

New weapon in the fight against cancer

New Australian drug shows positive response in patients with multiple myeloma blood cancer

Adaptimmune melanoma trial opening

Initial data from COMPLETE study on peripheral T-cell lymphoma presented at ICML 2011

Boehringer Ingelheim, Zealand Pharma partner to develop Type-2 diabetes and obesity agonists

Seattle Genetics brentuximab vedotin, dacetuzumab clinical data to be presented at ICML 2011

Potential new drug therapies targeting genetic mutations benefit lung-cancer patients

Sheep diagnoses breast cancer

Galectin strengthens cancer drug patent portfolio in Europe

OncoSec Medical third quarter net loss increases to $491,000

Biomoda receives U.S. patent to expand the use of CyPath assay for treatment of cancer

JEM published paper identifies new gene mutations in patients with chronic lymphocytic leukemia

Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

Policy issues related to dual-eligible patients, cancer medication coverage attract headlines

Sarcoma UK releases inspiring film about people's experiences of living with bone cancer

Second course of treatment could cure head and neck cancer

Cancer survivors and friends to attend San Diego's Survivor Beach event on June 19

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Hyperthermia prevents repair of tumor cells

Ambit Biosciences raises $30 million through Series D-2 equity financing

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in